Expertise in
1
conditions

Joseph Cheriyan

Hills Road, 
Cambridge, ENG, GB 
Expertise in
1
conditions
Hills Road, 
Cambridge, ENG, GB 

Overview

Joseph Cheriyan practices practicing medicine in Cambridge, United Kingdom.

Mr. Cheriyan is highly rated in 1 condition, according to our data. His clinical expertise encompasses Chronic Obstructive Pulmonary Disease (COPD), Hypertension, Necrosis, and Atherosclerosis.

He is actively involved in clinical research, co-authoring 72 peer reviewed articles and participating in 10 clinical trials.

Gender

Male

Locations

Hills Road, Cambridge, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Comparison of Optimal Hypertension Regimens (Part of the Ancestry Informative Markers in Hypertension (AIMHY) Programme - AIMHY-INFORM)
Comparison of Optimal Hypertension Regimens (Part of the Ancestry Informative Markers in Hypertension (AIMHY) Programme - AIMHY-INFORM)
Enrollment Status: Completed
Publish Date: September 05, 2025
Intervention Type: Drug
Study Drugs: Amlodipine, Lisinopril, Amiloride, Chlortalidone
Study Phase: Phase 4
Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes
Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes
Enrollment Status: Completed
Publish Date: June 10, 2024
Intervention Type: Other, Drug
Study Drug: IL-2
Study Phase: Phase 2
A Randomized, Repeat Dose, Open Label, Parallel Group, Multi-center Study to Evaluate the Effect of Daprodustat Compared to Darbepoetin Alfa on Forearm Blood Flow in Participants With Anemia of Chronic Kidney Disease That Are Not Dialysis Dependent
A Randomized, Repeat Dose, Open Label, Parallel Group, Multi-center Study to Evaluate the Effect of Daprodustat Compared to Darbepoetin Alfa on Forearm Blood Flow in Participants With Anemia of Chronic Kidney Disease That Are Not Dialysis Dependent
Enrollment Status: Terminated
Publish Date: March 27, 2024
Intervention Type: Drug
Study Phase: Phase 2
An Observational, Open-label Pilot Study to Evaluate the Effect of Standard-of-care Erythropoiesis-stimulating Agents (Darbepoetin Alfa) on Forearm Blood Flow in Nondialysis-dependent Subjects With Anaemia Associated With Chronic Kidney Disease.
An Observational, Open-label Pilot Study to Evaluate the Effect of Standard-of-care Erythropoiesis-stimulating Agents (Darbepoetin Alfa) on Forearm Blood Flow in Nondialysis-dependent Subjects With Anaemia Associated With Chronic Kidney Disease.
Enrollment Status: Completed
Publish Date: February 07, 2024
Intervention Type: Drug
A Series of Pilot Studies to Evaluate the Haemodynamic and Metabolic Effects of Apelin and Relaxin in Healthy Humans, Subjects With Increased Weight and Patients With Type 2 Diabetes Mellitus
A Series of Pilot Studies to Evaluate the Haemodynamic and Metabolic Effects of Apelin and Relaxin in Healthy Humans, Subjects With Increased Weight and Patients With Type 2 Diabetes Mellitus
Enrollment Status: Unknown
Publish Date: February 07, 2024
Intervention Type: Drug, Diagnostic test
Study Phase: Phase 2
A Cross-sectional REVEAL Sub-study Evaluating the Effect of Anacetrapib on Vascular Function and Arterial Stiffness [An Investigator Led Sub-study of HPS3/TIMI 55: REVEAL]
A Cross-sectional REVEAL Sub-study Evaluating the Effect of Anacetrapib on Vascular Function and Arterial Stiffness [An Investigator Led Sub-study of HPS3/TIMI 55: REVEAL]
Enrollment Status: Completed
Publish Date: February 07, 2024
Intervention Type: Drug
INvestigating the Lowest Threshold of Vascular bENefits From LDL Cholesterol Lowering With a PCSK9 mAb InhibiTor (Alirocumab) in healthY Volunteers
INvestigating the Lowest Threshold of Vascular bENefits From LDL Cholesterol Lowering With a PCSK9 mAb InhibiTor (Alirocumab) in healthY Volunteers
Enrollment Status: Completed
Publish Date: July 27, 2023
Intervention Type: Other, Drug
Study Phase: Not Applicable
A Mechanistic Study to Evaluate the Vasodilatory Effects of AZD3427 in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) and Patients With Heart Failure With Reduced Ejection Fraction (HFrEF)
A Mechanistic Study to Evaluate the Vasodilatory Effects of AZD3427 in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) and Patients With Heart Failure With Reduced Ejection Fraction (HFrEF)
Enrollment Status: Withdrawn
Publish Date: December 17, 2021
Intervention Type: Drug
Study Phase: Phase 1
Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes
Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes
Enrollment Status: Completed
Publish Date: September 14, 2021
Intervention Type: Drug
Study Drug: Proleukin
Study Phase: Phase 1/Phase 2
INvestigating the Lowest Threshold of Vascular bENefits From LDL Cholesterol Lowering With a PCSK9 mAb InhibiTor (Alirocumab) in Patients With Stable Cardiovascular Disease (INTENSITY-HIGH)
INvestigating the Lowest Threshold of Vascular bENefits From LDL Cholesterol Lowering With a PCSK9 mAb InhibiTor (Alirocumab) in Patients With Stable Cardiovascular Disease (INTENSITY-HIGH)
Enrollment Status: Unknown
Publish Date: July 23, 2021
Intervention Type: Drug
Study Phase: Not Applicable
View 9 Less Clinical Trials

72 Total Publications

Author's Reply to: "Comment on: Colchicine for the Secondary Prevention of Cardiovascular Diseases: A Cumulative-Dose Meta-analysis of Randomized Controlled Trials Including 31,397 Subjects Worldwide".
Author's Reply to: "Comment on: Colchicine for the Secondary Prevention of Cardiovascular Diseases: A Cumulative-Dose Meta-analysis of Randomized Controlled Trials Including 31,397 Subjects Worldwide".
Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions
Published: March 31, 2026

Frequently Asked Questions about Joseph Cheriyan

Is Joseph Cheriyan a top-rated expert for Chronic Obstructive Pulmonary Disease (COPD)?

MediFind is an objective health platform that identifies experts based on real-world data. Joseph Cheriyan is classified as an Advanced expert for Chronic Obstructive Pulmonary Disease (COPD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Joseph Cheriyan participate in research or clinical trials?

Yes. Joseph Cheriyan has published 72 articles and abstracts on conditions like Chronic Obstructive Pulmonary Disease (COPD). You can view a list of Joseph Cheriyan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cheriyan's expertise for a condition
ConditionClose
      View All 14 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile